Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit

Abstract

CsA-containing microspheres might be a promising formulation in the prevention of corneal graft rejection. Since the levels of CsA in blood were undetectable, this treatment might avoid the problems associated with systemic side effects.

Therapeutic and Toxicological Evaluations of Cyclosporine A Microspheres as a Treatment Vehicle for Uveitis in Rabbits

“…Rojas-Silva and colleagues reported on poly(dl-lactide-co-glycolide)co-polymer (PLGA) (50/50) microspheres for the treatment of keratoplasty rejection in the rabbit, which improved the local tolerance in comparison with a CyA oil solution. 14,15 Our previous report on the toxicity of poly(caprolactone-block-D,L-lactide) microspheres demonstrated that intravitreal injection of such particles in rabbits was a safe way to delivery CyA to the posterior segment of the rabbit eye. These results will enlighten us on the application of biodegradable poly(DL-lactide-co-glycolide)co-polymer microspheres containing CsA (CyA-PLGA-MS) in the treatment of uveitis.…”

Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral Drugs

“…liposomes and microparticles). These new pharmaceutical dosage forms appear to preserve the visual acuity and quality of life of patients; although it has been described that an intravitreal injection of particulate or vesicle dispersions requires submicronic size ranges to avoid interference with vision [39]. On the one hand, liposomal formulations can provide effective intravitreal concentrations of ganciclovir for 30 days with no sign of ocular toxicity [34].…”

Biodegradable Polymers for Ocular Drug Delivery

“…The microspheres show a sustained release of leuproline acetate for a period ranging from 1 to 3 months [30]. Intravitreal [8, 9, 31, 32, 33, 34]or subconjunctival [7, 35, 36, 37]administration of drug-loaded biodegradable microspheres has been reported.…”

“…Harper et al [36]prepared PLGA microspheres containing cyclosporin A and measured its concentration in the anterior chamber and cornea after subconjunctival injection. de Rojas Silva et al [37]reported on the feasibility of PLGA microspheres containing cyclosporin A in the prevention of corneal graft rejection.…”